The acquisition of patents and patent applications will complement Tandem’s intellectual property portfolio related to the novel technologies.

As part of the acquisition, Tandem has also obtained a license to 28 other US patents and patent applications owned by Smiths.

The license will provide Tandem to gain access to Smiths’ technologies and use them in the future for developing products in the field of ambulatory infusion pumps and related software and accessories for the treatment of diabetes.